Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 58Gastrointestinal 33Tumor-Agnostic 18Head & Neck 16Other solid neoplasm 14CNS 12Sarcoma 10Breast 8Genitourinary 5Lymphoid 4Gynecologic 3Plasma cell 2Dermatologic 2Other neoplasm 1Other hematologic neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Precancerous Conditions 1Esophageal Neoplasms 1Barrett Esophagus 1

Interventions

Biopsy 4Cyclophosphamide 3Microarray Analysis 2Methylprednisolone 2Filgrastim 2Colposcopy 2Carboplatin 2toripalimab 1tipifarnib 1sargramostim 1sapanisertib 1pyroxamide 1pirfenidone 1penpulimab 1palbociclib 1liposomal doxorubicin 1iodixanol 1human papillomavirus vaccine, TA 1artemisinin 1arginine butyrate 1Zoledronic Acid 1Vincristine 1Video-Assisted Surgery 1Topotecan 1Tetradecanoylphorbol Acetate 1Taxes 1Tacrolimus 1Specimen Handling 1Sorafenib 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Erlotinib Hydrochloride × Other neoplasm × Clear all
NCT00566800 2013-09-17

Erlotinib in Treating Patients With Barrett Esophagus

National Cancer Institute (NCI)

Phase 1 Unknown
25 enrolled
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡